Literature DB >> 10602558

Current Clinical Experience with Staphylokinase in Arterial Thrombosis.

.   

Abstract

Entities:  

Year:  1996        PMID： 10602558     DOI： 10.1007/BF00133072

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN： 0929-5305            Impact factor:   2.300


× No keyword cloud information.
  21 in total

Review 1.  Basic and clinical aspects of fibrinolysis and thrombolysis.

Authors:  D Collen; H R Lijnen
Journal:  Blood       Date:  1991-12-15       Impact factor: 22.113

Review 2.  Rationale for bolus t-PA therapy to improve efficacy and safety.

Authors:  G Agnelli
Journal:  Chest       Date:  1990-04       Impact factor: 9.410

3.  Recombinant staphylokinase variants with altered immunoreactivity. I: Construction and characterization.

Authors:  D Collen; R Bernaerts; P Declerck; F De Cock; E Demarsin; S Jenné; Y Laroche; H R Lijnen; K Silence; M Verstreken
Journal:  Circulation       Date:  1996-07-15       Impact factor: 29.690

4.  High yield production and purification of recombinant staphylokinase for thrombolytic therapy.

Authors:  B Schlott; M Hartmann; K H Gührs; E Birch-Hirschfeid; H D Pohl; S Vanderschueren; F Van de Werf; A Michoel; D Collen; D Behnke
Journal:  Biotechnology (N Y)       Date:  1994-02

Review 5.  Thrombolysis in acute myocardial infarction.

Authors:  H V Anderson; J T Willerson
Journal:  N Engl J Med       Date:  1993-09-02       Impact factor: 91.245

Review 6.  New developments in thrombolytic therapy.

Authors:  D C Collen; H K Gold
Journal:  Thromb Res Suppl       Date:  1990

7.  A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. The STAR Trial Group.

Authors:  S Vanderschueren; L Barrios; P Kerdsinchai; P Van den Heuvel; L Hermans; M Vrolix; F De Man; E Benit; L Muyldermans; D Collen
Journal:  Circulation       Date:  1995-10-15       Impact factor: 29.690

8.  Prevalence and induction of circulating antibodies against recombinant staphylokinase.

Authors:  P J Declerck; S Vanderschueren; J Billiet; H Moreau; D Collen
Journal:  Thromb Haemost       Date:  1994-01       Impact factor: 5.249

9.  On the immunogenicity of recombinant staphylokinase in patients and in animal models.

Authors:  S M Vanderschueren; J M Stassen; D Collen
Journal:  Thromb Haemost       Date:  1994-08       Impact factor: 5.249

Review 10.  Use of thrombolytic drugs in non-coronary disorders.

Authors:  M Verstraete
Journal:  Drugs       Date:  1989-11       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.